Sees Q2 revenue $830M-$850M, consensus $818.55M. The company said, “Net sales guidance includes an estimated second-quarter 2026 benefit of approximately 1.3 percentage points based on current foreign currency exchange rates.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical reports Q1 adjusted EPS $2.13, consensus $1.68
- WST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- West Pharmaceutical price target raised to $275 from $265 at Barclays
- West Pharmaceutical expands Damastown, Dublin facility
- Orderly Leadership Transition and Reaffirmed 2026 Targets Underpin Buy Rating on West Pharmaceutical